- All the pediatric subjects (aged 3-15 years) whom an investigator prescribes the first
gabapentin (tablets, syrup, and switch to syrup from tablet) should be registered
consecutively until the number of subjects reaches target number in order to extract
patients enrolled into the investigation at random.
- Patients who have been enrolled in the drug use investigation of Gabapen tablets in
adults (protocol No. A9451163).
- Patients who receive Gabapen tablets or syrup before, except for switched from tablets